Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab

Bone Marrow Transplant. 2016 Nov;51(11):1510-1512. doi: 10.1038/bmt.2016.157. Epub 2016 Jun 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab / adverse effects
  • Alemtuzumab / therapeutic use
  • Antibiotic Prophylaxis
  • Antilymphocyte Serum / adverse effects
  • Antilymphocyte Serum / therapeutic use
  • Antineoplastic Agents, Immunological
  • Bacteremia / etiology*
  • Child
  • Fever / chemically induced*
  • Fever / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Immunosuppressive Agents
  • Risk
  • Sepsis
  • Transplantation, Homologous

Substances

  • Antilymphocyte Serum
  • Antineoplastic Agents, Immunological
  • Immunosuppressive Agents
  • Alemtuzumab